PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Chen, T.* ; Wang, L.* ; Xie, G.* ; Kristal, B.S.* ; Zheng, X.* ; Sun, T.* ; Arnold, M. ; Louie, G.* ; Li, M.* ; Wu, L.* ; MahmoudianDehkordi, S.* ; Sniatynski, M.J.* ; Borkowski, K.* ; Guo, Q.* ; Kuang, J.* ; Wang, J.* ; Nho, K.* ; Ren, Z.* ; Kueider-Paisley, A.* ; Blach, C.* ; Kaddurah-Daouk, R.* ; Jia, W.*

Serum bile acids improve prediction of Alzheimer's progression in a sex-dependent manner.

Adv. Sci.:e2306576 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Sex disparities in serum bile acid (BA) levels and Alzheimer's disease (AD) prevalence have been established. However, the precise link between changes in serum BAs and AD development remains elusive. Here, authors quantitatively determined 33 serum BAs and 58 BA features in 4 219 samples collected from 1 180 participants from the Alzheimer's Disease Neuroimaging Initiative. The findings revealed that these BA features exhibited significant correlations with clinical stages, encompassing cognitively normal (CN), early and late mild cognitive impairment, and AD, as well as cognitive performance. Importantly, these associations are more pronounced in men than women. Among participants with progressive disease stages (n = 660), BAs underwent early changes in men, occurring before AD. By incorporating BA features into diagnostic and predictive models, positive enhancements are achieved for all models. The area under the receiver operating characteristic curve improved from 0.78 to 0.91 for men and from 0.76 to 0.83 for women for the differentiation of CN and AD. Additionally, the key findings are validated in a subset of participants (n = 578) with cerebrospinal fluid amyloid-beta and tau levels. These findings underscore the role of BAs in AD progression, offering potential improvements in the accuracy of AD prediction.
Impact Factor
Scopus SNIP
Altmetric
15.100
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Alzheimer's Disease ; Bile Acid ; Cholesterol ; Mild Cognitive Impairment ; Sex Difference; Alzheimers-disease; Metabolomics; Biomarkers
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2198-3844
e-ISSN 2198-3844
Zeitschrift Advanced science
Quellenangaben Band: , Heft: , Seiten: , Artikelnummer: e2306576 Supplement: ,
Verlag Wiley
Verlagsort Weinheim
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Computational Biology (ICB)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-503891-001
Förderungen Alzheimer's Disease Metabolomics Consortium (ADMC)
National Institute of Biomedical Imaging and Bioengineering
National Institute on Aging
DOD ADNI (Department of Defense)
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)
FNIH
NIA
National Institutes of Health (NIH)
National Science Foundation
DOI 10.1002/advs.202306576
WOS ID 001126504000001
Scopus ID 85179918977
PubMed ID 38093507
Erfassungsdatum 2023-12-20
[➜Korrektur melden]